I. Definition & Epidemiology: Clinical Relevance
Erectile dysfunction (ED) is defined as the persistent inability to attain or maintain a penile erection of sufficient rigidity and duration to permit satisfactory sexual intercourse. It is not merely a sexual complaint but often an early sentinel symptom of systemic vascular, neurologic, endocrine, or psychogenic disease.
- Prevalence: Affects ~30% of men aged 40–70 years; increases with age (20% in men 40–49 vs >65% in >70 years) [1].
- Duration Threshold for Diagnosis: ≥3 months of persistent symptoms is required to distinguish transient, stress-related ED from chronic organic or mixed etiology—aligning with International Index of Erectile Function (IIEF) diagnostic criteria and DSM-5–TR standards.
Key Insight for Clinicians:
New-onset ED in men <55 years without obvious psychologic triggers has a positive predictive value of 40–60% for future major adverse cardiovascular events (MACE) within 2–5 years—often preceding angina or MI by 2–3 years [2,3]. This reflects shared pathophysiology: endothelial dysfunction, oxidative stress, and atherosclerosis affecting the smaller penile arteries (~1–2 mm diameter) before coronary arteries (>2.5 mm).
II. Diagnostic Evaluation: A Structured Approach
A. History Taking: Beyond the Surface
- Sexual History:
- Onset (acute vs chronic), pattern (total vs situational), nocturnal/early morning erections, libido, ejaculatory function, and psychological correlates.
- Use validated tools to quantify severity:
- IIEF-5 (International Index of Erectile Function–5): Gold standard for diagnosis & monitoring. Score ≤21 defines ED; ≤7 = severe [4].
- Erectile Function Domain (EFD) sub-scale from IIEF for treatment response assessment.
- Partner involvement improves diagnostic accuracy, adherence, and outcomes—especially in psychogenic cases.
- Medical & Psychosocial History:
- Screen for comorbidities:ComorbidityPrevalence in EDPathophysiologic LinkType 2 diabetes (T2DM)58–75%Endothelial dysfunction, neuropathy, hypogonadismHypertension32–46%Arterial stiffening, reduced perfusionDyslipidemia~40%Atherosclerotic plaque formationMetabolic syndrome>60%Insulin resistance + chronic inflammationDepression/anxiety35–47% (bidirectional)Serotonergic modulation of erection; performance anxiety
- Medications: Antihypertensives (β-blockers, thiazides), SSRIs, 5α-reductase inhibitors, antipsychotics.
- Lifestyle: Smoking (>20 pack-years OR = 3.1 for ED) [5], alcohol >14 drinks/week, sedentary behavior.
B. Physical Examination: Targeted Assessment
- Genital exam:
- Penile deformities (Peyronie’s: fibrotic plaques, chordee), phimosis, testicular volume (<15 mL suggests hypogonadism), epididymal abnormalities.
- Digital rectal exam (DRE): Prostate size/tenderness (chronic prostatitis linked to ED), sphincter tone (neurologic disease).
- Secondary Cause Clues:
- Gynecomastia, body hair distribution (hypogonadotropic hypogonadism)
- Carotid bruits, peripheral pulses (vasculogenic ED)
- Neurologic: anal wink reflex, bulbocavernosus reflex (for neurogenic ED)
- Cachexia, thyromegaly (endocrine)
C. Laboratory Testing: Guideline-Recommended
Based on AUA/EAU guidelines [6,7]:
| Test | Indication | Clinical Utility |
|---|---|---|
| Fasting glucose or HbA1c | All patients | T2DM present in ~50% of men with ED; prediabetes (HbA1c 5.7–6.4%) increases ED risk by 30% [8] |
| Lipid panel | All patients | Low HDL (<40 mg/dL) and elevated triglycerides (>150 mg/dL) strongly predict vasculogenic ED [9] |
| Morning total testosterone | Men with low libido, erectile difficulty, fatigue, or obesity | Hypogonadism (T <300 ng/dL) present in ~25% of ED cases; total T alone insufficient—consider SHBG, free/testosterone index if borderline [10] |
| Prolactin & TSH | Selective: if hypogonadal symptoms + normal T | Hyperprolactinemia (e.g., pituitary adenoma) suppresses GnRH; hypothyroidism impairs NO synthase |
Note: Routine PSA is not indicated solely for ED evaluation—per AUA guidelines.
D. Advanced Testing: Reserved for Complex Cases
Indications include: suspected vascular/neurologic ED, failed first-line therapies, or prior to surgical/interventional procedures.
| Test | Clinical Role | Limitations |
|---|---|---|
| Nocturnal Penile Tumescence & Rigidity (NPTR) | Differentiates psychogenic vs organic ED; preserves nocturnal erections in psychogenic cases | Operator-dependent, limited availability, low specificity if only rigidity measured [11] |
| Penile Doppler Ultrasound | Evaluates arterial inflow (peak systolic velocity ≥30 cm/s = adequate), venous occlusion (veno-occlusive dysfunction: PSV <30 cm/s + rapid decline) | Requires intracavernosal injection of vasoactive agent (e.g., papaverine/phentolamine); false negatives with anxiety, poor technique [12] |
| Intracavernosal Injection Test | Bedside assessment of vascular competence; erection ≥70% rigidity for 5+ min suggests adequate arterial inflow | Not standardized for routine use; contraindicated in sickle cell, anticoagulation |
III. Cardiovascular Risk Assessment: A Critical Diagnostic Opportunity
ED is an independent predictor of cardiovascular disease (CVD). The Endothelial Dysfunction Hypothesis posits that penile arteries manifest CVD earlier due to anatomical and hemodynamic factors [2].
Risk Stratification Framework (Adapted from AUA/ACC/AHA guidelines) [3,13]
| Patient Category | ASCVD Risk* | Recommended Workup | Management of Sexual Activity |
|---|---|---|---|
| No overt CVD, low ASCVD risk (<5%) | <5% | No routine cardiac testing if vasculogenic mechanism unconfirmed; if confirmed (e.g., abnormal Doppler), consider coronary artery calcium (CAC) scoring | CAC = 0: Lifestyle intervention only; sexual activity safe CAC >0: Initiate statin + lifestyle |
| Borderline–intermediate risk (5–20%) | 5–20% | CAC scoring preferred (Class I recommendation per 2018 ACC/AHA) [14] | CAC 1–100: Moderate-intensity statin + preventive cardiology referral CAC >100: High-intensity statin + low-dose aspirin (if no bleeding risk) + cardiology referral. Stress testing (e.g., exercise ECG or MPI) if symptoms or high CAC |
| High ASCVD risk (>20%) | >20% | Urgent cardiology referral; consider coronary CT angiography if intermediate pretest probability | Sexual activity considered moderate intensity (METs ~3–4); obtain stress test if symptomatic or high-risk biomarkers (e.g., NT-proBNP ↑) |
| Known CVD + new-onset ED | Varies by stability | – Stable angina: Stress testing if symptoms limit activity – HF (LVEF <40%): Echo + cardiology consult – Recent MI (<90 days): Avoid sexual activity until clinically stable [15] | Initiate PDE5 inhibitors only after cardiac optimization; avoid in unstable CAD, recent MI/stroke, severe arrhythmia |
*ASCVD = Atherosclerotic Cardiovascular Disease (10-year risk via Pooled Cohort Equations)
Key Evidence: Men with ED and no known CVD have 1.5–2.0x increased risk of future CVD events [2]; the association persists after adjusting for age, smoking, diabetes.
IV. Management: Stepwise, Individualized Approach
A. Foundational Interventions
- Treat underlying etiology:
- T2DM: Achieve HbA1c <7%—each 1% reduction lowers ED risk by 10% [8]
- Hypogonadism: Testosterone replacement only in confirmed hypogonadal men (serum T <300 ng/dL + symptoms); improves libido more than erectile function [16]. Avoid in prostate cancer, severe heart failure.
- Obstructive sleep apnea: CPAP therapy improves endothelial function and nocturnal erections [17]
- Lifestyle modification:
- Exercise: 160 min/week moderate activity improves IIEF scores by 2.5 points vs control (RCT, J Urol 2022) [18]
- Weight loss: 10% reduction in BMI improves erectile function by 30% in obese men (Diabetes Care 2021)
- Diet: Mediterranean diet associated with 40% lower ED incidence vs Western diet (Eur Urol 2023 meta-analysis)
B. Pharmacotherapy: First-Line Options
| PDE5 Inhibitor | Dosing | Onset | Duration | Key Considerations |
|---|---|---|---|---|
| Sildenafil | 50 mg (25–100 mg); take 30–60 min pre-intercourse | 30–60 min | 4–5 h | Avoid high-fat meals (delays absorption) |
| Tadalafil | PRN: 10 mg (5–20 mg); daily: 2.5–5 mg qAM | 30–120 min | 36 h (PRN) ~24 h (daily) | Preferred in men with BPH (improves IPSS, flow rate) |
| Vardenafil | 10 mg (2.5–20 mg); take 30–60 min pre-intercourse | 30–60 min | 4–7 h | Lower bioavailability; avoid in hepatic impairment |
| Avanafil | 100 mg (50–200 mg); take 15–30 min pre-intercourse | 15–30 min | 6 h | Fastest onset; lowest incidence of visual disturbances |
Contraindications to PDE5 Inhibitors:
- Absolute: Nitrates (any form), guanylate cyclase stimulators (sildenafil, riociguat)
- Relative: Stable angina on α-blockers (space doses by 4 h), hypotension (BP <90 mmHg systolic), recent MI/stroke (<6 months)
Evidence Update on CV Safety:
- Meta-analysis of 37 RCTs (JAMA Intern Med 2023): PDE5 inhibitor use associated with 28% lower MACE risk vs placebo (RR 0.72, 95% CI 0.61–0.85), especially in diabetics [19].
- Avoid combination with α-blockers without dose titration: e.g., tadalafil + doxazosin may cause syncope; start α-blocker at lowest dose.
C. Second- and Third-Line Therapies
| Modality | Indications | Efficacy | Risks |
|---|---|---|---|
| Intraurethral alprostadil (MUSE®) | Patients refusing injections; mild ED | 30–50% success (vs 60–80% for injection) | Dizziness, urethral burning, penile pain |
| Intracavernosal injection (alprostadil ± papaverine/phentolamine) | Failed oral therapy; vascular surgery evaluation | >80% efficacy; rigid erection in <15 min | Pain (20–30%), fibrosis (<1%/yr), priapism (<2%) |
| Vacuum erection device (VED) | Medical contraindications to drugs; post-prostatectomy | 80–90% achieving intromission | Bruising, cold sensation,ejaculatory dysfunction |
| Penile prosthesis (inflatable or malleable) | Refractory ED after counseling; Peyronie’s with deformity | >90% satisfaction at 5 years | Mechanical failure (2–5%/yr), infection (<3%), erosion |
Special Populations:
- Post-prostatectomy: PDE5 inhibitors may aid penile rehabilitation if nerve-sparing; evidence strongest for tadalafil daily (PRODIGY trial) [20]
- Chronic kidney disease (CKD): PDE5 inhibitors effective down to eGFR 30 mL/min; avoid avanafil if eGFR <15 mL/min
- Psychogenic ED: Combination therapy (PDE5i + cognitive behavioral therapy) superior to monotherapy (Int J Impot Res 2022)
V. Monitoring & Long-Term Follow-Up
- Reassess in 3 months: Evaluate efficacy, adherence, side effects
- Annual screening for comorbidities: Lipids, HbA1c, testosterone (if symptomatic), BP
- Consider cardiovascular risk re-stratification every 2–4 years in men with ED and ASCVD 5–20% risk
Key Clinical Takeaways for the Practicing Physician
- ED is often the first manifestati on of subclinical CVD—a “canary in the coal mine.”
- CAC scoring refines risk stratification in asymptomatic men with ED and intermediate ASCVD risk.
- PDE5 inhibitors are first-line, safe (except with nitrates), and may improve long-term CV outcomes.
- Lifestyle modification is foundational—equally important as pharmacotherapy.
- Shared decision-making is critical: Tailor treatment to patient values, sexual goals, comorbidities, and partner involvement.
Sources & Guidelines Cited
- American Urological Association (AUA) Guideline: Diagnosis and Treatment of Erectile Dysfunction (2023 Update)
- European Association of Urology (EAU): Sexual and Reproductive Medicine Guidelines (2024)
- ACC/AHA Guideline: Coronary Artery Calcium Risk Stratification (Jama 2018; Circulation 2023)
- Endocrine Society: Testosterone Therapy in Adult Men (2018, reaffirmed 2023)
- meta-analysis: PDE5 Inhibitors and Cardiovascular Outcomes, JAMA Intern Med 2023;183(7):622–631
- PRODIGY Trial: Tadalafil for Post-Prostatectomy ED, Eur Urol 2021;79(4):517–525
This summary reflects current evidence as of Q2 2024. Always consult institutional protocols and drug labeling for final prescribing decisions.
